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Paget’s disease of bone (PDB) is a chronic skeletal disorder that can
affect one or several bones in individuals older than 55 y of age.
PDB-like changes have been reported in archaeological remains as
old as Roman, although accurate diagnosis and natural history of
the disease is lacking. Six skeletons from a collection of 130 exca-
vated at Norton Priory in the North West of England, which dates
to medieval times, show atypical and extensive pathological
changes resembling contemporary PDB affecting as many as
75% of individual skeletons. Disease prevalence in the remaining
collection is high, at least 16% of adults, with age at death esti-
mations as low as 35 y. Despite these atypical features, paleopro-
teomic analysis identified sequestosome 1 (SQSTM1) or p62, a
protein central to the pathological milieu of PDB, as one of the
few noncollagenous human sequences preserved in skeletal sam-
ples. Targeted proteomic analysis detected >60% of the ancient
p62 primary sequence, with Western blotting indicating p62 abnor-
malities, including in dentition. Direct sequencing of ancient DNA
excluded contemporary PDB-associated SQSTM1mutations. Our ob-
servations indicate that the ancient p62 protein is likely modified
within its C-terminal ubiquitin-associated domain. Ancient miRNAs
were remarkably preserved in an osteosarcoma from a skeleton
with extensive disease, with miR-16 expression consistent with that
reported in contemporary PDB-associated bone tumors. Our work
displays the use of proteomics to inform diagnosis of ancient dis-
eases such as atypical PDB, which has unusual features presumably
potentiated by yet-unidentified environmental or genetic factors.
Paget’s disease | osteosarcoma | p62 | SQSTM1 | paleoproteomic
Paget’s disease of bone (PDB) is the second most commonmetabolic bone disorder (1). The condition is characterized
by focal abnormalities in bone remodeling. Contemporary PDB
typically affects one or several bones in individuals older than
55 y of age (2). Pathogenesis involves three phases, starting with
a lytic phase in which bone turnover is markedly increased and
increased resorption occurs through the action of abnormal
hypernucleated osteoclasts (3). A second mixed phase of lytic and
osteoblastic activity is dominated by rapid increases in osteoblast
activity giving rise to abnormal bone with irregular deposition of
collagen fibers. Finally, in a sclerotic phase, bone formation pre-
dominates, with newly formed bone being disorganized (woven)
and mechanically weaker, overall resulting in skeletal lesions with
abnormal architecture and predisposition to fracture. PDB com-
monly affects the femur, tibia, pelvis, skull, and spine but is rarely
seen in non–weight-bearing bones such as the fibula (4). Affected
individuals can experience complications such as bone pain, bone
deformity, nerve compression syndromes, and susceptibility to
fractures. Osteosarcoma is a rare but severe complication (1).
Western Europe is thought to be the origin of PDB, specifi-
cally the United Kingdom (5). Populations of British descent
report the highest prevalence, currently 1–2% in individuals
older than 55 y (6). The North West of England represents a
particular hotspot, whereas PDB is rare in Scandinavia, Asia,
and Africa (1). Incidence and severity of newly diagnosed cases
has decreased; for example, the incidence of PDB in the city of
Lancaster has decreased from 8.3% in the 1970s to 0.8% at
present (7, 8). Such secular changes suggest a role for currently
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undefined but important changes in environmental factors that
affect genetically predisposed individuals (1, 8). Infection with
paramyxoviruses such as measles, supraphysiological biomechan-
ical loading, and other environmental triggers have been consid-
ered, but evidence is inconclusive (1).
Genetic factors in the etiology of PDB are well defined. As
many as 40% of affected individuals have relatives with PDB.
Susceptibility is determined by driver mutations in genes relevant
to osteoclast function, which include colony-stimulating factor 1
(CSF1), dendrocyte-expressed seven transmembrane protein
(DCSTAMP), TNF receptor superfamily member 11a (TNFRSF11A),
TNF receptor superfamily member 11b (TNFRSF11B), optineurin
(OPTN), nucleoporin 205 (NUP205), Ras and Rab interactor 3
(RIN3), and promyelocytic leukemia (PML) (1, 6). As many as 50%
of familial cases, as well as a smaller number of sporadic cases, carry
heterozygous mutations affecting the sequestosome 1 (SQSTM1)
gene that encodes the SQSTM1 or p62 protein. Such variants im-
pact p62 in a domain-specific manner, generally being associated
with missense and truncating mutations within the C-terminal
ubiquitin-associated (UBA) domain (residues 387–436) (9, 10).
Patients with SQSTM1 mutations are typically diagnosed earlier
than those without, with mutation status alone playing a major role
in determining the disease phenotype in patients (11, 12). Mice with
a proline-to-leucine mutation at codon 394 of sqstm1, equivalent to
the most common P392L mutation in humans, develop an age-
associated bone disorder with similarity to PDB (13). This bone
disorder can be prevented by infusion with zoledronic acid, which is
the first-line treatment for PDB in humans (14). SQSTM1 is also
relevant to disease etiology in PDB patients without mutations. For
example, p62 is overexpressed in patient-derived cells regardless of
mutation status, and p62 immunoreactivity is a feature of the nu-
clear inclusion bodies that characterize pagetic osteoclasts (15, 16).
miRNA dysregulation has also been shown to play a role, with
down-regulation of miR-16 observed in PDB (17). Increased miR-
16 expression was also observed in PDB-associated osteosarcoma
(PDB-OS) compared with nontransformed pagetic bone lesions
(17). MiR-16 is a negative regulator of the SQSTM1 transcript (18).
PDB-like features based on macroscopic and radiographic
changes resembling those in the contemporary disorder have
been reported in archaeological remains dating as far back as
Roman, with the highest number of cases identified as medieval
(1066–1538 AD) (19). Norton Priory in the North West of Eng-
land is one of the most excavated monastic sites in Europe, with a
collection of 130 skeletons dating to the medieval period. A pre-
vious review of the collection identified pathological changes re-
sembling PDB in six individuals, ∼5% of the adult sample, which
is more than double than in comparable excavations in the North
East of England (20). Our reanalysis indicated that skeletal in-
volvement in the six cases at Norton Priory is more extensive than
previously reported, raising questions about whether the disorder
was a form of ancient PDB or another bone disease.
Paleoproteomics is a relatively new field that has demon-
strated that proteins, typically abundant structural proteins such
as collagens, resist taphonomy and persist in mineralized tissues
over many years (21). MS-based protein sequencing provides
insights into species identification and evolutionary relationships
and potentially helps to identify human disease, especially in
conditions in which ancient DNAmay be degraded. Paleoproteomic
studies focus on the most abundant bone proteins such as collagen;
however, noncollagen protein sequences can also be recovered
from archaeological samples. For example, peptide sequences
from more than 100 different proteins were recovered from a
43,000-y-old mammoth femur (22). Western blotting detected
prostate-specific antigen in bone from an ancient specimen with
metastatic prostate cancer (23). Proteomic analysis of a 2,000-y-
old bone tumor identified several contemporary biomarkers (24).
These proteins contain an additional level of information that
offers opportunities for exploring the history and evolution of disease,
potentially even through the detection of mutations or modifi-
cations within protein sequences (25).
We reasoned that bone-specific proteomes might provide in-
sights into the skeletal disorder at Norton Priory. We catalog the
highly unusual phenotypic features of the bone disorder within the
Norton Priory collection, highlighting similarities and important
differences vs. contemporary forms of PDB. We show that pale-
oproteomic analysis (sequencing of ancient p62 protein) and
analysis of ancient small RNAs can be used to support the di-
agnosis of a PDB-like disorder several hundred years after death.
Results
Atypical Features of a PDB-Like Disorder at Norton Priory. A review
of six adult skeletons from the Norton Priory collection (130 ar-
ticulated skeletons, 114 of which are adult) identified macro-
scopic changes resembling contemporary PDB (20). Reanalysis
using radiography indicates that the disease in the six cases is
unusually extensive (SI Appendix, Table S1). For example, SK101
is an adult male assessed at 45–49 y of age dated to the 15th
century and is one of the most extensively affected individuals,
with PDB-like changes involving 75% of his skeleton (Fig. 1A).
SK29 is also markedly affected with PDB-like pathology (75% of
the skeleton), although, in this case, most changes were detected
only by radiography (Fig. 1B). SK29 exhibits an osteosarcoma to
both os coxae (Fig. 1F) (20). Accelerator MS (AMS) radiocar-
bon dating and stable isotopic analysis (C, N, Sr, and O) indi-
cated that all six skeletons are medieval in age (1050–1390 AD),
had a mainly marine-based diet, and identified as local to the
North West of England (SI Appendix, Tables S2 and S3).
We extended the study of six skeletons to include additional
remains in the collection. We analyzed in detail a further 12 skel-
etons that displayed visible lesions similar to contemporary PDB.
Each of the 12 skeletons were subjected to complete macroscopic
and radiographic review with additional AMS radiocarbon dating
and isotope analysis. SK37, an adult male assessed at 30–35 y of
age, shows distinct porous macroscopic changes involving 40% of
his skeleton (Fig. 1C). Internal structural changes of the bone dis-
ease can be clearly observed in his right clavicle that were not ev-
ident in a comparable sample from an unaffected individual (Fig.
1C). Radiographic imaging identified PDB-like lesions affecting
75% of the affected skeleton, including thickened and enlarged
bone in the sacrum (Fig. 1D) and os coxae (Fig. 1E).
Radiocarbon analysis confirmed that the additional 12 skeletons
are also medieval in age, with the combined 18 skeletons covering
450 y of Norton Priory’s history (1020–1479 AD). Some individuals
appear to have lived during the same period of time (SI Appendix,
Table S2). Carbon (13C) and nitrogen (15N) stable isotope analysis
for the additional 12 skeletons identified high levels of nitrogen,
again revealing a marine-based diet, which is typical of a monastic
lifestyle (SI Appendix, Table S3). Consistent with the slight male
predilection seen in contemporary PDB, there was higher preva-
lence of affected males (n = 15) than females (n = 3) in the
18 skeletons. Norton Priory is a monastic site that presents a bias
toward adult males overall (male, n = 85; female, n = 29). Patho-
logical changes were extensive in all of the additional 12 skeletons,
with 40% of each skeleton displaying macroscopic PDB-like lesions.
Radiographic analysis highlighted that 75% of the skeleton was
affected in some cases. Identification of 18 medieval skeletons with
PDB-like lesions creates a new population prevalence of 14% (18 of
130), or 16% of the adult sample (18 of 114) at Norton Priory.
Overall age at death assessment was 35–59 y of age, including 13 of
18 individuals under the age of 50 y (SI Appendix, Table S2).
Compared with contemporary PDB, the skeletal disorder at Norton
Priory is therefore characterized by unusually extensive pathology
and high prevalence with relatively low estimated age at death.
Skeletal distribution of disease in the 18 skeletons generally
follows contemporary distribution, i.e., femur, pelvis, skull, and
spine (SI Appendix, Table S4). Involvement of the fibulae is rarely
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reported in contemporary PDB, but here it is one of the most
commonly affected bones. Complications reported in patients with
contemporary PDB include osteoarthritis, deafness, fractures, de-
formity, and malignancy. In the Norton Priory skeletons, very few
complications are observed, with a lack of evidence of deformity in
weight-bearing bones (e.g., tibia and/or femur) or pseudofractures.
Malignant transformation occurs in 1:1,000 of contemporary PDB
patients. SK29 harbors an osteosarcoma in the pelvis, which is
particularly rare for the archaeological record (Fig. 1F). Although
skeletal changes in the Norton Priory remains broadly resemble
those seen in contemporary PDB, there are many atypical features
within the Norton Priory remains (SI Appendix, Table S4).
Abnormal SQSTM1 (p62) Is Preserved in Skeletal Samples from the
PBD-Like Disorder. We performed molecular diagnosis of the
reported bone disorder. We reasoned that bone-specific pro-
teomes might provide insights into disease etiology. For our
paleoproteomic analysis, we accessed a sample of petrous bone
(part of the temporal bone) from one of the originally described
six skeletons. SK101 shows extensive macroscopic and radio-
graphic evidence of disease, with most bones affected (Fig. 1A
and SI Appendix, Table S1). The cranium was among the most
highly affected areas. Extracts from the petrous sample revealed
complex protein patterns on SDS/PAGE with a high degree of
smearing (Fig. 2A). Complete protein extracts from different
fractions were subject to LC-MS/MS to catalog constituent
proteins, including the insoluble pellet fraction resulting after
buffer extractions of the bone matrix (Fig. 2A). A total of 19 hu-
man proteins were detected with a minimum of two peptide se-
quences within this pellet fraction. The majority of the identified
proteins were collagens and cytoskeletal components (SI Appen-
dix, Table S5). Peptide sequences matching to human p62 (8%
sequence coverage) were detected in the pellet fraction from three
exclusive unique peptides. This preferential preservation of p62—
a protein not previously reported in paleoproteomic analysis to
our knowledge—in SK101 petrous suggests that the associated
disorder was likely an ancient form of PDB in this individual.
We also performed Western blots using the pellet fraction
from SK101 petrous with mouse anti-p62 antibodies. Two strongly
immunoreactive bands were detected, migrating with higher mo-
lecular weight than a ∼62-kDa control band from a human cell
line (Fig. 2B). Weaker immunoreactivity corresponding to these
higher molecular weight forms of ancient p62 was also detected in
the TCA-precipitated phosphate extract from SK101 petrous (Fig.
2A). Ancient p62 was not detected by a rabbit polyclonal antibody
raised against the C-terminal UBA domain of the human protein
(residues 387–436), although this antibody also readily detected a
control ∼62-kDa band from human cells (Fig. 2B). To determine
if abnormally migrating p62 protein was a common feature of
other skeletons in the collection, we expanded our Western blotting
with the mouse antibody to include four additional samples from
the original six skeletons. For one of these skeletons, SK52, a
sample of petrous bone was available. For the other three skeletons
(SK22, SK29, SK35), we sampled teeth. Although petrous from
SK52 was p62-negative, a tooth sample from SK29 produced an
equivalent immunoreactive profile to SK101, with the two abnor-
mally migrating higher molecular weight forms of ancient p62
readily detected (Fig. 2C and Table 1).
Fig. 1. Skeletal distribution of macroscopic changes (red), internal lytic changes identified by radiographic analysis (yellow), and unaffected bones (green) of
a PDB-like disorder in SK101 (A) and SK29 (B). (C) Macroscopic observation of internal structural changes in the right clavicle of SK37 (Left) compared with the
normal cortical and trabecular structure of an unaffected right clavicle (Right; SK50). Radiographic imaging of SK37 sacrum (D) and hip (E). (F) Macroscopic
observation of osteosarcoma (arrowhead) in the pelvis of SK29. The extracortical portion of the tumor exhibits a slight radiant alignment of bone that is often
referred to as a “sunburst” appearance. Reprinted with permission of the Norton Priory Museum Trust.
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The rabbit antibody also failed to detect ancient p62 from the
tooth of SK29. Positive detection of p62 with the mouse antibody in
teeth is unexpected, as pagetic changes, although reported to affect
the jaw, have rarely been reported in dental pulp. This finding
presumably represents involvement of odontoclasts. Previous dental
pulp paleoproteomic analysis did not detect p62 protein sequences
(26, 27). Blotting was expanded to petrous samples from an addi-
tional two cases within the collection that showed evidence of dis-
ease (SK32, SK37) plus two cases with no obvious pathology (SK27,
SK28). We detected weak p62 reactivity using the mouse antibody
in the insoluble pellet fraction of SK37 (Table 1). We were also able
to analyze insoluble pellet fractions from femur samples of three of
the original six skeletons (SK101, SK52, SK35). Although SK101
petrous bone was previously found to be p62-positive (Fig. 2C), the
corresponding femur sample was negative (Table 1). In contrast,
SK35 femur was found to be p62-positive (Table 1) despite the
corresponding tooth sample being negative (Fig. 2C). A total of
four of seven skeletons with evidence of PDB-like changes
showed p62 immunoreactivity by Western blot with mouse anti-
p62 in at least one sample tested. Both skeletons without evi-
dence of pathology showed no immunoreactivity (Table 1). We
speculate that the variability of ancient p62 detection in the
affected skeletons likely reflects differences in protein preser-
vation resulting from varied burial conditions. Inadvertent
sampling of skeletal areas with different degrees of disease
activity may also be a factor, as it was not feasible to radio-
graphically assess all bone samples before drilling.
Primary Sequence of the Ancient p62 Protein. LC-MS/MS shotgun
analysis using the linear trap quadrupole (LTQ) Orbitrap Velos
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151 CSVCEGKGLH RGHTKLAFPS PFGHLSEGFS HSRWLRKVKH GHFGWPGWEM 200
201 GPPGNWSPRP PRAGEARPGP TAESASGPSE DPSVNFLKNV GESVAAALSP 250
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D
Fig. 2. Proteomic analysis of ancient skeletal samples. (A) SDS/PAGE and silver stain analysis of sequential fractions of proteins extracted from SK101 petrous
bone, with molecular weight markers (in kilodaltons) shown to the left. Lane 1 is guanidine-HCl extract. Lane 2 is guanidine-HCl/EDTA extract. Lane 3 is
phosphate buffer/EDTA extract. Lane 4 is insoluble pellet. In each lane, 10% of total protein extracted from 50 mg bone was loaded. (B) Western blot of
insoluble pellet fraction (from lane 4) using mouse and rabbit anti-p62 antibodies, with HEK293T cell extract as positive control. (C) Western blot of SK101 and
SK52 petrous bone using mouse anti-p62 antibodies, plus Western blot of SK29, SK22, and SK35 teeth extract (insoluble pellet) using mouse anti-
p62 antibodies, with HEK293T cell extract as positive control. (D) Combined MS data indicating WT ancient human p62 protein sequence detected (shaded)
from SK101 petrous (insoluble pellet) fraction.
Table 1. Paget’s-like changes, p62 reactivity and endogenous DNA in bone and
tooth samples
Skeleton
Macroscopic/radiographic
Paget’s-like changes Samples (p62 reactivity*) Samples (endogenous DNA†)
SK101 Yes‡ Petrous (+), Femur (−) Petrous (32.1%)
SK52 Yes Petrous (−), Femur (−) Petrous (47.2%)
SK29 Yes Tooth (+) Tooth (4.1%)
SK22 Yes Tooth (−) Tooth (26.8%)
SK35 Yes Tooth (−), Femur (+) Tooth (1.3%)
SK55 Yes — Rib (0.0004%)
SK32 Yes Petrous (−) —
SK37 Yes Petrous (+) —
SK27 No Petrous (−) —
SK28 No Petrous (−) —
(+), positive; (−), negative; —, not tested.
*p62 immunoreactivity in the indicated samples was assessed by Western blotting with mouse-anti-
p62 antibodies.
†Endogenous DNA content for different skeletal samples as indicated.
‡Indicates clear Paget’s like macroscopic and/or radiographic changes in bone.
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mass spectrometer with tryptic digest detected three unique peptide
sequences corresponding to human p62 (SI Appendix, Table S5). To
provide additional protein sequence data, we extended this analysis
to SDS/PAGE gel slices limited to an area that included both of the
p62 immunoreactive bands from SK101. Separation and individual
identification of the bands was not achieved as a result of masking
by the protein smear (Fig. 2A). Peptide sequencing was performed
by using the LTQ Orbitrap Velos with tryptic digestion (SI Ap-
pendix, Fig. S1A) and an Orbitrap Fusion Lumos mass spectrometer
with elastase digestion (SI Appendix, Fig. S1B). Many more pep-
tides from the 440-residue human p62 sequence were identified,
which yielded a total combined sequence coverage of 60% (266 of
440 residues; Fig. 2D). Comparable analysis of SK29 tooth samples
also detected 10% of the human p62 sequence with no additional
coverage compared with SK101. Error-tolerant searches provided
no evidence of any p62 sequence variants. The combined MS
analyses confirmed that the ancient p62 sequence is WT and intact
between residues 342 and 395 but did not detect any protein se-
quence beyond I395, the region corresponding to the majority of the
C-terminal UBA domain (SI Appendix, Fig. S2). This is the region of
p62 removed by a PDB-associated E396X truncating mutation
known to be associated with an early age at onset (∼47 y) and high
number of bones affected (∼6) in contemporary PDB patients (10).
Sequencing of Ancient DNA. Targeted proteomics directed cDNA
sequencing to investigate the possible presence of the E396X
mutation (T insertion at +1225). For ancient DNA analysis,
petrous bone or tooth samples were sourced from the original six
skeletons. For SK55 (not tested in the blotting study), an addi-
tional sample of rib bone was available. Samples were cleaned
and UV-treated before sequencing yielded estimates of endog-
enous DNA (Table 1). These values ranged from 47% (SK52
petrous) to 0.0004% (SK55 rib) with average read lengths of
50 bp and damage patterns consistent with DNA extracted from
ancient samples. There was no obvious correlation between
quality of ancient DNA and detection of p62 by Western blot in
corresponding samples.
Given the degraded nature of ancient DNA and varying de-
grees of endogenous DNA preservation, primers were designed
to create an amplicon with a maximum size of 70–80 bp covering
the genomic region that includes residues 392–404 of p62. An
additional set of pigtail primers were designed to allow for
clearer direct sequencing. Sequencing was successful for five of
six samples (Fig. 3A). In all cases, only WT SQSTM1 sequence
was identified, including nucleotides corresponding to P392–
E396, which is consistent with protein sequencing (Fig. 2D).
There was no evidence of insertion or deletion. The contempo-
rary PDB-associated E396X truncating mutation, as well as
P392L, S399P, and M404V/T missense mutations that map to
this region, were excluded (SI Appendix, Fig. S2).
Western Blot Insights into Ancient p62 Sequences. The failure of the
rabbit antibody raised against residues 387–436, i.e., the UBA
domain, to detect ancient p62 supported the possible mutation/
deletion of SQSTM1 or modification of a corresponding rabbit
epitope (Fig. 2B). To understand the primary structure of the
ancient p62 protein, we fine-mapped the rabbit antibody epitope.
C-terminal deletion analysis showed that the rabbit antibody was
able to detect a recombinant p62 (1–404) sequence but not p62
(1–395), which is equivalent to the E396X mutant (Fig. 3B). We
pinpointed an epitope between residues 396 and 404 (SI Ap-
pendix, Fig. S2). PDB-associated variants located within this
epitope (S399P, M404V, M404T) that are generated as GST-
fusion proteins in Escherichia coli were detected by the rabbit
antibody, further excluding mutation of this region as the reason
for failed detection of ancient p62 by the antibody. Other com-
mon missense mutations including P387L, P392L, G411S, and
G425R were included in the panel (SI Appendix, Fig. S2). The
mouse and rabbit antibodies successfully recognized all missense
mutants tested (Fig. 3C). The PDB-associated E396X truncating
mutant equivalent to the p62 (1–395) protein sequence used in
the epitope mapping that removes the majority of the UBA
domain was not recognized by the rabbit antibody (Fig. 3C). This
mutation had already been excluded by DNA sequencing. We
conclude that the failure to detect ancient p62 with the rabbit
antibody where the mouse antibody gave reactivity is unlikely to
be caused by a mutation affecting the rabbit epitope (residues
396–404) with corresponding DNA being intact. Rather, failure
to detect is likely a result of epitope masking by taphonomic
changes that are diagenetic in origin, or there is an undefined
disease-associated posttranslational modification(s) of the an-
cient p62 protein that is a feature of the disorder.
A
B C
P392 E396 S399 M404
WT 1-395 1-404 1-410 WT E396X P387L P392L S399P M404V M404T G411S G425R
- GST-p62
(mouse)
- GST-p62
(rabbit)
Fig. 3. Apparent absence of mutations in ancient p62. (A) Representative targeted DNA sequencing of ancient SQSTM1, in this case corresponding to
residues 392–404 of human p62. Presence of WT codons at known PDB mutation sites are indicated. (B) Western blotting using recombinant human GST-
p62 protein sequences as indicated. WT represents full-length WT 440-residue sequence. Mouse and rabbit anti-p62 antibodies located an epitope for the
latter between residues 396 and 404. (C) Western blot detection of human GST-p62 protein sequences with PDB mutations as indicated, using mouse and
rabbit anti-p62 antibodies.
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Analysis of Ancient Small RNAs in Osteosarcoma. A rare complica-
tion of PDB is malignant transformation. We recently reported
changes in miRNAs in PDB-OS. We detected a high expression
of miR-16 in PDB-OS compared with samples from nontransformed
pagetic bone lesions, indicating that miR-16 may serve as a bio-
marker of malignant transformation (17). One of the p62-positive
skeletons, SK29, shows osteosarcoma on both sides of the pelvis
(Fig. 1F). This finding provided an opportunity to explore ancient
miRNAs. Next-generation sequencing obtained 6.6 million reads
in the SK29 osteosarcoma. Mapping against the human genome
and corresponding annotations showed clustering of miRNA ex-
pression in noncancerous controls compared with SK29 osteo-
sarcoma (Fig. 4A). This quality-control step is consistent with
previous small RNA sequencing studies reporting controls and
disease. Of the 3.7% genome matching reads in the SK29 osteo-
sarcoma, 71% mapped to miRNA loci and 0.5% mapped to tRNA
loci. Differential expression analysis showed a high expression of
miR-144 (Fig. 4B), a low expression of miR-335 (Fig. 4C), a high
expression of miR-374 (Fig. 4D), and a high expression of miR-
451 in SK29 osteosarcoma. Quantitative differential expression
analysis showed that miR-16 was highly expressed in the ancient
osteosarcoma compared with a nontransformed femoral PDB
lesion from the same individual (Fig. 4F). To the best of our
knowledge, this is the first demonstration of successful extraction of
ancient miRNAs and tRNAs from archaeological bone samples.
Discussion
Several of our observations support the notion that Norton
Priory in the North West of England was a medieval hotspot for
an atypical form of PDB. This bone disorder presumably rep-
resents a variant of contemporary PDB. There are considerable
phenotypic differences associated with the Norton Priory remains
compared with modern-day PDB. These differences include ex-
tensive disease (75% of bones in some affected skeletons), low
age-at-death estimations (13 of 18 individuals younger than 50 y),
and high disease prevalence in the adult sample (16%), but little
evidence of bone deformities. Macroscopic and radiographic
analysis combined with characteristic pathological changes and
molecular signatures support a retrospective diagnosis of an
atypical form of PDB. Internal structural changes of bones from
the collection are consistent with those expected for PDB, with
macroscopic thickening and enlargement of bone, as is the
presence of an osteosarcoma in one of the affected skeletons.
Within this osteosarcoma, increased miR-16 expression is con-
sistent with that reported in contemporary PDB (17).
Detection of ancient p62 as one of the few noncollagenous
proteins in skeletal samples (bones and teeth) based on a com-
bination of peptide sequencing and Western blotting is strongly
indicative of a diagnosis of PDB, not least because, to the best
of our knowledge, no other paleoproteomic analysis has detected
this PDB-associated protein. Although protein retrieval is
buffer- and protocol-dependent, we extensively reviewed pub-
lished studies describing proteomics of ancient bone and teeth,
including those that used comparable methods to ours, and
found no previous reports of detection of ancient p62 protein. In
our study, p62 protein sequences were detected by using two
different mass spectrometers in unconnected laboratories from
more than one tissue sample, in extracts generated by several
investigators on different occasions. Unlike ancient DNA anal-
ysis, protein detection does not rely on amplification, countering
the possibility of contamination of samples. Our findings are
highly significant, as they represent one of the first molecular di-
agnoses of an ancient disorder based largely on protein sequence-
based methods. Those methods indicate that ancient remains
affected by other skeletal disorders may also hold a “chemical
memory” that is amenable to proteomic interrogation.
Several speculations remain regarding the detection and ob-
served properties of the ancient p62 protein. p62 was variably
detected, having been observed in only 4 of 10 samples tested
from 4 of 7 affected individuals. We consider that a combination
of differential preservation of the skeletons throughout burial
with the fact that, although disease was extensive, not all samples
tested may have been affected by pagetic changes may be an
explanation. PDB is principally an osteoclast disorder, with
p62 pathology being a feature of this cell type (16). Osteoclasts
are rare in human bones that are unaffected by PDB.
p62 was detected in tooth samples even though PDB is not
classically associated with involvement of dentition. Pagetic
changes have been reported in teeth in rare cases of the disorder
(28, 29). Roles for p62 in the regulation of autophagy in human
dental pulp cells have also been described (30). It is possible that
the atypical and extensive nature of this ancient form of PDB
accounts for pathological accumulation of p62 protein in denti-
tion. It is tempting to speculate that ancient and even contem-
porary teeth may more broadly act as a “storehouse” for the
study of human skeletal disorders.
Ancient p62 survived burial and was well preserved for hun-
dreds of years despite the fact that it is a simple intracellular
scaffold protein, rather than an abundant and intractable struc-
tural protein such as collagen. We found enrichment of ancient
p62 in the insoluble pellet fraction remaining after the standard
buffer extractions. The characteristic p62-positive inclusions
noted in PDB osteoclasts have previously been described based
on EM to have organized viral-like paracrystalline morphology,
which may underlie enhanced stability of the protein in the
pagetic state (31). At the molecular level, p62 can form oligo-
meric filamentous structures and can undergo phase separation
to form droplets with liquid-like properties (32, 33). These
properties may again relate to p62 stability and be enhanced in
the pagetic state, in which the protein is overexpressed (15).
Accumulation of protein aggregates within inclusion bodies is a
common feature of a range of neurodegenerative disorders with
disease-associated misfolded proteins deposited in insoluble
forms in the nucleus and cytoplasm (34). Ancient PDB may
similarly represent a p62 “proteinopathy.”
Ancient p62 aberrantly migrates on SDS/PAGE–Western blot,
with two prominent bands differentially detected by antibodies
directed against different epitopes and with higher than expected
denatured molecular weight. Sequencing of ancient DNA and
blotting studies of recombinant mutant proteins with the differ-
ent antibodies excludes common disease-associated missense
mutations, although these would not be expected to account for
the observed aberrant migration of the protein. Targeted DNA
sequencing did not provide any evidence for gross genomic al-
terations within the p62 UBA domain, at least in the region
encoding residues 392–404. In our proteomic analysis, we found
no evidence of peptide sequences supportive of this alteration or
of aberrant splicing. Although PDB-associated splice site muta-
tions have been identified that give rise to shorter p62 sequences,
the genomic region corresponding to and around residue E396
does not appear to harbor cryptic splice sites. Cryptic splicing
events of SQSTM1 cannot be completely discounted, such as
splicing imparted by other genetic variants (10, 35, 36). We be-
lieve altered properties of the ancient p62 are most likely a result
of taphonomic changes in the protein or some form of (possibly
disease-related) posttranslational modification(s). Regarding
taphonomic changes, from scrutiny of proteomic data, we found
no evidence that the ancient p62 protein was heavily oxidized
and/or deamidated. There are various reports in the literature of
SDS-stable higher molecular weight forms of p62 with little
comment on its nature or biological significance, which variously
conclude that exposure to cigarette smoke, UV light, or cellular
aging can induce covalent p62 oligomers (37). Significant dis-
crete mass shift (as much as ∼10 kDa per modification) can
occur as a result of covalent linkage with ubiquitin-like modifiers
that could also mask antibody epitopes. Our proteomic data
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Fig. 4. Ancient miRNA analysis in SK29, which harbors an osteosarcoma in the pelvis. (A) Hierarchical cluster analysis of differentially expressed miRNAs (y axis)
between contemporary controls and SK29 PDB-OS (x-axis). Z-score refers to high (red) and low (blue) miRNA expression using normalized values compared with the
mean of total sequencing reads. (B) Box plot of controls vs. SK29 PDB-OS shows that miR-144 is highly expressed in SK29 PDB-OS. (C) Box plot of controls vs. SK29 PDB-
OS shows that miR-335 is down-regulated in SK29 PDB-OS. (D) Box plot of controls vs. SK29 PDB-OS shows that miR-374 is highly expressed in SK29 PDB-OS. (E) Box plot
of controls vs. SK29 PDB-OS shows that miR-451 is highly expressed in SK29 PDB-OS. (F) Digital PCR for miR-16 expression performed with pooled cDNA obtained from
contemporary controls, cDNA obtained from a PDB lesion in SK29, and cDNA obtained from PDB-OS in SK29. Data are reported as copies per microliter as calculated by
Poisson distribution. Error bars represent SD. Consistent with previous data, miR-16 is highly expressed in PDB-OS compared with nontransformed PDB.
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provided no evidence of ubiquitin, SUMO, or NEDD8 se-
quences in p62-containing fractions, and Western blots failed to
detect ubiquitin immunoreactivity. Other covalent modifications
such as cross-links via transglutamination cannot be discounted,
and other contemporary genetic abnormalities could be at play.
Aside from involvement of and alterations in the ancient p62
protein, we also detected ancient miRNAs and tRNAs from
skeletal samples. In line with our recent analysis of contemporary
PDB-OS, miR-16 was highly expressed in samples extracted from
an ancient osteosarcoma compared with extracts from a non-
transformed PDB lesion (17). p62 serves as a signaling hub that
can regulate various pathways relevant to cancer biology. Pre-
vious studies have demonstrated that the SQSTM1 transcript
that encodes p62 is negatively regulated by miR-16 (18). miR-16
expression changes in PDB-OS may not only represent a bio-
marker but may be directly relevant to tumorigenesis. It is salient
to note that miRNAs are 10 times more stable than mRNA
transcripts, and, unlike DNA, RNA is less prone to depurination,
suggesting that dry environments may reduce the rate of degra-
dation (38–40). Where ancient DNA and protein sequencing
produces inconclusive data in archaeological studies, we suggest
investigation of miRNAs.
Ancient PDB at Norton Priory is phenotypically unusual and
apparently unique in the North West of England. Ancient PDB
required radiographic analysis to confirm its presence/extent in
many cases. It is possible that cases of PDB in other medieval
skeletal collections have been overlooked, and a closer reeval-
uation of these is now merited. Although, as in many pop-
ulations, the incidence of PDB has significantly decreased in the
North West of England in the past few decades, this region has
traditionally represented a hotspot for the disorder, suggesting
that changing local environmental factors may represent a major
but unexplained trigger. Strontium and oxygen isotope analysis
has identified that at least five of the skeletons examined in our
study are local to this area, supporting this modern etiology. It is
also possible that the high prevalence of PDB in the Norton
Priory collection was the result of accumulation of cases from a
wider distribution as a result of the priory being seen as a “re-
ferral center” for the management of painful bones. Additional
Sr and O isotope analysis is required to test this hypothesis.
Some studies have suggested a role for paramyxoviruses in
PDB etiology, supported by the presence of virus-like nuclear
inclusions in pagetic osteoclasts (41). Other studies have failed to
confirm these findings and have raised questions regarding the
nature of the inclusion bodies (42). We failed to detect any virus
protein sequences in our proteomic analyses. Dietary factors
such as calcium and/or vitamin D have also been implicated in
disease etiology. The individuals in the Norton Priory collection
were likely of a high status based on their distinct and highly
decorated stone coffins and prominent burial locations within
the priory walls. Stable isotope analysis (C, N) indicate a mainly
marine-based diet that was unlikely to be nutrient-deficient, with
values similar to King Richard III and the medieval Bishops of
Whithorn in Scotland (43, 44). Unknown genetic factors could
also have played a role, with recent studies showing variants in
genes other than SQSTM1, such as zinc finger protein 687
(ZNF687), to be associated with severe PDB, with a high number
of affected bones; however, in this case, mutations rarely occur in
PDB patients without neoplastic degeneration (45). Clearly, other
genes interact with SQSTM1 to modify disease phenotypes, and a
more comprehensive understanding of contemporary PDB genetics
will direct future studies of ancient forms of the disorder (46).
We propose that, across several centuries of the medieval
period, PDB at Norton Priory was very different from the dis-
order seen in the present day. There are currently uncharac-
terized environmental factors possibly affecting genetically
predisposed individuals to die of a highly unusual variant of the
contemporary disease. Identification of these factors could have
significant implications for understanding and managing PDB
several hundreds of years after the dissolution of the priory.
Materials and Methods
Skeletal Remains. Skeletons are from the Norton Priory Human Skeletal
Collection, which is housed at Norton Priory Museum and Gardens in Run-
corn, UK. The skeletons are the subject of a new archaeological research
framework encouraged by the Trust of Norton Priory Museum and Gardens.
The Augustinian Priory was founded in 1115 AD and later relocated to its
current location in 1134 AD. Archaeological excavations in the 1970s and
1980s revealed that burials began in the late 12th century and continued until
the dissolution of monasteries in 1536 AD. The excavations resulted in the
disinterment of 130 articulated skeletons. The deceased are believed to be
Augustinian Canons or important benefactors of the priory (47). A recent
examination of the collection reports a profile typical of a monastic site,
with 85 adult male and 29 adult female burials. The remaining burials are
children, inclusive of one fetus found in the abdomen of a female burial. In
this study, 18 adult skeletons were investigated in detail (SI Appendix,
Table S2).
Contemporary Bone Samples. Ethical approval to obtain and study human
material was granted by the University of East Anglia Faculty ofMedicine and
Health Sciences Research Ethics Committee (reference 2013/2014–22 HT).
Bone samples (n = 5) were collected as part of a previous study (17). All
individuals provided written informed consent.
Recombinant Protein Expression in E. coli. GST-tagged human p62 proteins
were expressed from plasmid pGEX-4T1 in XL10-Gold E. coli (48). Briefly, 10-mL
cultures were grown in LB containing 100 μg/mL ampicillin overnight at
37 °C in a shaking incubator. Overexpression cultures (10 mL) were set up by
using 200 μL of overnight culture in 10 mL LB containing 100 μg/mL ampi-
cillin. These were grown for 3 h at 37 °C in a shaking incubator and then
induced with 400 μM IPTG for a further 3 h.
Macroscopic Osteological Analysis. Skeletons (N = 18) were examined for
distinct visual macroscopic lesions resembling PDB. This included changes in
the size, thickness, and vascularity of the bones. A visual inventory was
completed for each skeleton. This permitted the documentation of the
skeletal distribution of the observed macroscopic changes observed for each
individual. One skeleton included in this study (SK29) exhibits marked lesions
of an osteosarcoma to both os coxae (20).
Radiographic Osteological Analysis. When macroscopic analysis had been
completed, skeletons were subjected to radiological review. The radiological
features observed in the internal structure of ancient bones with PDB-like
changes have been described by several authors and include a lack of uni-
formity in areas of increased bone density, cortical thickening, and disor-
ganization of the architecture (49). The early lesions of contemporary PDB
are predominately lytic and are often limited to the endosteum or central
layers of the cortex (50). Radiography permits the detection of earlier phases
of PDB that may not be detected by macroscopic analysis alone. Skeletons
were subjected to full radiographic review (anteroposteriorly and medi-
olaterally) using the Faxitron series X-ray system. To document the pre-
sentation and distribution of the radiological lesions, a visual inventory was
completed for each skeleton.
AMS Radiocarbon Analysis. A single tooth was extracted from 15 skeletons.
Molar roots were submitted for AMS radiocarbon dating to establish their
age and stable isotopic analysis (carbon and nitrogen) for paleodiet re-
construction to Beta Analytic. Molar crowns were submitted to the Natural
Environment Research Council Isotope Laboratory (Nottingham, UK) to study
their enamel composition to obtain their strontium isotope (87Sr/86Sr) and
oxygen isotope (δ18O) values. Teeth were second permanent molars and
premolars, as they represent a time frame of 2.5–8.5 y based on the crown
formation (51). This analysis was used to estimate the individual’s geo-
graphical provenance and potential mobility, depending on the parent rock/
soil types where these individuals lived as children (52).
Protein Extraction from Ancient Bones/Teeth. Protein was extracted as de-
scribed previously (53). Sampling preference was for the petrous portion of
the temporal bone. In cases in which petrous was not available, teeth were
sampled. When teeth were not available, the most intact bone available was
sampled (e.g., femur). Samples were cleaned and UV-treated before sub-
sampling was carried out for DNA extraction or protein extraction. Samples
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were finely ground with a chilled pestle and mortar. Samples were washed
for 24 h in 5 volumes (weight to volume) of extraction buffer A (4M guanidine-
HCl, 20 mM NaH2PO4, 30 mM Na2HPO4, pH 7.4, plus 1:1,000 mammalian pro-
tease inhibitor mixture; Sigma) under constant agitation at 4 °C. Bone was then
pelleted by centrifugation at 4 °C, and the supernatant was removed. This was
followed by extraction with five volumes of buffer B (buffer A plus 300 mM
EDTA) under constant agitation at 4 °C for 24 h. Supernatant was removed as
for the previous step. The resultant pellet was washed with five volumes of
autoclaved distilled water three times before storage at 20 °C. A total of 20 mg
of dried bone matrix extract (BME) was sonicated for 2 × 15 s on ice in 100 μL
neutral 50 mM phosphate buffer, 10 mM EDTA, containing 1:1,000 mammalian
protease inhibitor mixture. The supernatant was then removed. Solubilized
protein was precipitated with TCA (8% wt/vol final concentration). The
remaining BME pellet was also retained.
SDS/PAGE and Western Blotting. Protein samples were solubilized by using
SDS/PAGE loading buffer containing urea (150 mM Tris, 2.5% wt/vol SDS,
3%wt/vol DTT, 10% vol/vol 2-mercaptoethanol, 20% vol/vol glycerol, 8M urea,
0.1% wt/vol bromophenol blue, pH 6.8). Proteins were separated by gel
electrophoresis on 5–20% acrylamide gradient gels with silver staining de-
tection using a GE Healthcare PlusOne silver stain kit or transferred to ni-
trocellulose for Western blotting. p62-positive control for Western blot was
a total protein lysate of the human embryonic kidney cell line HEK293T. A
mouse monoclonal p62 antibody (610833; BD Biosciences) and rabbit polyclonal
p62 antibody (BML-PW9860; Enzo Life Sciences) were used to probe for p62.
HRP-conjugated secondary antibodies were appropriate to primary antibody
species (Dako). Secondary antibodies were detected via chemiluminescence
using Western Lightning ECL (Perkin-Elmer). Recombinant GST-p62 proteins
were similarly detected by SDS/PAGE and Western blotting.
Recombinant GST-p62 Purification and Western Blotting. All GST-p62 mutants
were produced by site-directed mutagenesis of WT human sequence (1–440)
in pGEX-4T-1 using the QuikChange 2 method (Agilent). Bacterial pellets con-
taining expressed proteins were sonicated in 1 mL 10 mM Tris·HCl, 150 mM
sodium chloride, pH 7.5, 0.1% (vol/vol) Triton X-100 (TBST), followed by cen-
trifugation at 16,000 × g, 4 °C for 10 min. The lysates were incubatedwith 50 μL
of preequilibrated glutathione-Sepharose to collect the GST-tagged recombi-
nant proteins. Sepharose pellets were washed three times in TBST, and the
proteins were then eluted with SDS/PAGE sample buffer. Samples were re-
solved on 5–20% acrylamide SDS/PAGE gradient gels and Western-blotted.
Protein MS. Complete ancient protein extracts were subjected to LC-MS/MS
analysis by electrophoresing the sample ∼0.5 cm in to the resolving gel.
After staining (0.1% wt/vol Coomassie blue, 10% vol/vol methanol, 10% vol/vol
glacial acetic acid) and destaining (10% wt/vol methanol, 10% vol/vol gla-
cial acetic acid), gel slices containing the protein mixtures were excised. In
some cases, gel slices limited to an area including both ancient p62 immu-
noreactive bands were also analyzed. For shotgun proteomic analysis using
the LTQ Orbitrap Velos mass spectrometer (Thermo Fisher Scientific), sam-
ples containing protein mixtures were digested with trypsin with subsequent
LC-MS/MS analysis using an RSLC nano HPLC system (Dionex) as previously
described (54). Raw data files were processed using Proteome Discoverer
(v1.4.0.288; Thermo Fisher Scientific) and searched using Mascot (v2.2.04;
Matrix Science) against UniprotHuman_2015_02 (67,911 entries) assuming
semitrypsin digestion (55). Peptide tolerance was set to 10 ppm, and MS/MS
tolerance was set to 0.02 Da. Scaffold Q+S (v4.4.1.1; Proteome Software) was
used to validate MS/MS-based peptide and protein identification from Pro-
teome Discoverer (56). Peptide identification was accepted if peptides could
be established at >95% probability, with a minimum of two peptides re-
quired for protein identification. Targeted LC-MS/MS data of p62-containing
gel slices was generated on an Orbitrap Fusion Lumos mass spectrometer
following digest of reduced (DTT) and alkylated (iodoacetamide) samples
using a standard gel-digestion protocol and elastase to maximize sequence
coverage (53, 57). Peptides were separated on a nEASY spray column (Thermo
Fisher Scientific) and analyzed on a Dionex Ultimate 3000/Orbitrap Fusion
Lumos (Thermo Fisher Scientific) using standard parameters. MS data were
analyzed with PEAKS Studio 8.5 (Bioinformatics Solutions). Mass tolerances
were set to 10 ppm/0.5 Da (MS1/MS2). No cleavage specificity was defined.
Carbamidomethylation was set as fixed. Modification, deamidation, and ox-
idation were variable. Peptide false discovery rate was adjusted to 1%.
Sequencing of Ancient DNA. Bone/tooth samples were cleaned and UV-
treated. DNA was extracted by using an optimized protocol developed
previously (58). Quantification of each extract and the control ladder was
performed on a Bioanalyzer 2100 (Agilent) using a DNA 1000 chip. The ef-
ficiency of recovery for each fragment was calculated by dividing the con-
centration of DNA in the extract by that of the control ladder. DNA was
stored at −20 °C. Single-stranded libraries were generated as previously
described (59). Libraries were sequenced on a NextSeq 500 (Illumina). Pri-
mers used to create the SQSTM1 amplicon and pigtail primers to allow
clearer direct sequencing are detailed in SI Appendix, Table S6.
Sequencing of Ancient Small RNAs. A bone sample was collected from an os-
teosarcoma lesion in the pelvis of SK29, with a further sample collected from the
femur thatwas affectedbyPDB in the same individual. Bonewas cleanedandUV-
treated before homogenization under liquid nitrogen conditions using the
BioPulverizer (BioSpec). Total RNA was extracted by using the miRCURY RNA
isolation kit (Exiqon) according to the manufacturer’s instructions. RNA con-
centration and integrity was measured on a NanoDrop 8000 Spectrophotometer
(Thermo Fisher Scientific) and visually assessed by agarose gel electrophoresis
with ethidium bromide staining. RNA was stored at −80 °C. Libraries using 5′
and 3′ high definition adapters were generated as previously described (60, 61).
Libraries were sequenced on a HiSeq 2500 (Illumina).
Bioinformatics. Raw FASTQ files were converted to FASTA format. Reads
containing unassigned nucleotides were excluded. The 3′ adapter was
trimmed by using perfect sequence similarity to the first 8 nt of the 3′ HiSeq
2500 adapter (TGGAATTC). The high definition signatures (four assigned
degenerate nucleotides at the ligating ends) of the reads were also trimmed.
SRNAs were mapped full length with no mismatches to the human genome
(v38) and corresponding annotations using PatMaN (62). The latest set of
human miRNAs were downloaded from miRBase (v21) (63). Normalization
and differential expression analysis was performed by using DESeq2 (v1.2.10)
(64). Independent filtering was used to remove low-expressing transcripts in
normalized counts. miRNAs were considered differentially expressed if they
had a P value <0.05, <5% false discovery rate according to the Benjamini–
Hochberg procedure, and greater than twofold change in expression.
Digital PCR. Total RNA was quantified by density measurement after sepa-
ration by agarose gel electrophoresis with ethidium bromide staining. Equal
amounts of RNA were reverse-transcribed using the TaqMan advanced
miRNA cDNA synthesis kit (Thermo Fisher Scientific). Differential expression
ofmiR-16was validated in triplicate by using TaqManmiRNA advanced assays
(Thermo Fisher Scientific). Digital PCR was performed on the QuantStudio 3D
Digital PCR System using the GeneAmp PCR System 9700 (Thermo Fisher
Scientific). After PCR, the chips were imaged on the QuantStudio 3D In-
strument, which assesses the raw data and calculates the concentration of the
cDNA sequence targeted by FAM- and VIC-labeled probes by Poisson dis-
tribution (65). For more in-depth analysis, the QuantStudio 3D AnalysisSuite
was used to report the data as copies per microliter. The probe sequence
used was miR-16–5p (5′-UAGCAGCACGUAAAUAUUGGCG-3′).
Data Availability. Proteomic data are available on ProteomeXchange under
accession number PXD011743 (66). Sequencing data are available on the
Gene Expression Omnibus database under accession numbers GSE87021
and GSE118540 (67).
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